3SBio to Go Private

The Chinese biotechnology company will soon be de-listed.

Eric Volkman
Eric Volkman
Feb 8, 2013 at 9:37PM
Health Care

3SBio (UNKNOWN:SSRX.DL) will no longer trade as a public company.  \The China-based firm announced that it will be taken off the market by a group captained by CEO Jing Lou, in addition to that nation's CITIC Capital. The buyout will see the group absorb 3SBio stock in exchange for $2.20 per ordinary share and $15.40 per American Depositary Receipt.

The latter price represents a premium of approximately 12% over 3SBio's most recent closing price on the Nasdaq. All told, the transaction should amount to around $340 million.

Jing's investor group already controls roughly 18% of the company.